Details

Autor(en) / Beteiligte

• Wallace, Gregory
• Rosen, Nelson
• Towbin, Alexander J
• Jodele, Sonata
• Myers, Kasiani C
• Davies, Stella M
• Flannery, Amanda
• Gurria, Juan P

Titel

Pneumatosis intestinalis after hematopoietic stem cell transplantation: When not doing anything is good enough

Ist Teil von

• Journal of pediatric surgery, 2021-11, Vol.56 (11), p.2073-2077

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •Pneumatosis intestinalis occurs in stem cell transplant recipient receiving steroids.•Unlike with NEC, pneumatosis intestinalis rarely poses clinical risk after transplant.•Majority of transplant patients with pneumatosis do not require any interventions.•Surgical evaluation is indicated based on symptoms and not pneumatosis presence alone.•Personalized management approach is based on surgical risk and benefit assessment. Pneumatosis intestinalis (PI) has been reported in hematopoietic stem cell transplant recipients (HSCT) since 1980s and at present there is no uniform consensus of the significance and management of this condition. We retrospectively reviewed medical records of 990 consecutive pediatric HSCT recipients and examined data for clinical PI presentation, management and outcomes PI was identified in 53 patients (5.4%), mainly allogeneic HSCT recipients receiving systemic steroids. Abdominal X-ray was the main diagnostic modality. Forty-seven patients (89%) were evaluated because of clinical concerns and others were identified as incidental findings. Pneumoperitoneum was reported in 15 patients (28%). None of these patients had signs of acute abdomen. The majority of patients (43/53, 81%) had no targeted clinical intervention for PI and resolved PI in a median of 15 days (IQR 3–61). Surgery consult was only requested for 7/53 (13%) patients, three of whom had evidence of pneumoperitoneum. None of these patients required any surgical interventions. Pneumatosis intestinalis commonly occurs in HSCT recipient receiving steroids, but unlike with NEC, PI rarely poses clinical risk after transplant. The majority of HSCT recipients with PI require only close monitoring without interventions. Surgical evaluation should be based on clinical symptoms and not PI presence alone.